NCT06034457Completed
Testing the Effectiveness of WW Clinic GLP1
24 Week External Single-arm Study Testing the Effectiveness of WW GLP1 Behavioral Program + Sequence Medical Weight Management on Weight Loss and Related Outcomes
Source: ClinicalTrials.gov · Last updated 19 Dec 2025
Brief summary (registry, in English)
The study objective is to evaluate the efficacy of the WeightWatchers (WW) GLP-1 behavioral program + WW Clinic (formerly known as Sequence medical weight management program) on weight loss and related outcomes. Participants will be invited to take part and answer surveys at 0, 12 and 24 weeks.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 180 (actual)
- First submitted
- 24 Aug 2023
- Start date
- 18 Jan 2024
- Primary completion date
- 17 Oct 2024
- Lead sponsor
- The Cleveland Clinic
- Diseases
- Obesity
- NCT number
- NCT06034457
What you commit to
- Study type: Observational
- Participants enrolled: 180
- From 18 Jan 2024 to the primary completion date, 17 Oct 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous surgical obesity treatment
- Use of other anti-obesity medication in last 90 days
Other illness
- Diabetes
- Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2
- History of pancreatitis within 180 days
Other
- Use of GLP-1 within the last 180 days
- Lost weight \>11 lbs in the last 90 days
- Pregnant, breastfeeding, intends to become pregnant, of child-bearing potential and not using a highly effective contraceptive method
Who the study is looking for
- 18 years or older
- BMI of \>30 or BMI of \>27 with one or more weight related medically qualifying condition (hypertension, dyslipidemia, sleep apnea, cardiovascular disease)
- Access to a smartphone or tablet that runs iOS/iPadOS 15.0 or later, or Android 7.0 or later
- A prescription for Wegovy, Mounjaro, or Zepbound
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cleveland Clinic Coordinator of this site? Confirm its status | Cleveland | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.